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A B S T R A C T
Background
This is an updated version of the original Cochrane review published in 2005 on selective serotonin re-uptake inhibitors (SSRIs) for
preventing migraine and tension-type headache. The original review has been split in two parts and this review now only regards
migraine prevention. Another updated review is under development to cover tension-type headache.
Migraine is a common disorder. The chronic forms are associated with disability and have a high economic impact. In view of discoveries
about the role of serotonin and other neurotransmitters in pain mechanisms, selective serotonin re-uptake inhibitors (SSRIs) and
serotonin-norepinephrine reuptake inhibitors (SNRIs) have been evaluated for the prevention of migraine.
Objectives
To determine the efficacy and tolerability of SSRIs and SNRIs compared to placebo and other active interventions in the prevention
of episodic and chronic migraine in adults.
Search methods
For the original review, we searchedMEDLINE (1966 to January 2004), EMBASE (1994 toMay 2003), the Cochrane Central Register
of Controlled Trials (CENTRAL 2003, Issue 4), and Headache Quarterly (1990 to 2003). For this update, we applied a revised search
strategy to reflect the broader type of intervention (SSRIs and SNRIs). We searched CENTRAL (2014, Issue 10), MEDLINE (1946
to November 2014), EMBASE (1980 to November 2014), and PsycINFO (1987 to November 2014). We also checked the reference
lists of retrieved articles and searched trial registries for ongoing trials.
Selection criteria
We included randomised controlled trials comparing SSRIs or SNRIs with any type of control intervention in participants 18 years
and older of either sex with migraine.
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Data collection and analysis
Two authors independently extracted data (migraine frequency, index, intensity, and duration; use of symptomatic/analgesic medication;
days off work; quality of life; mood improvement; cost-effectiveness; and adverse events) and assessed the risk of bias of trials. The
primary outcome of this updated review is migraine frequency.
Main results
The original review included eight studies on migraine. Overall, we now include 11 studies on five SSRIs and one SNRI with a total
of 585 participants. Six studies were placebo-controlled, four compared a SSRI or SNRI to amitriptyline, and one was a head-to-head
comparison (escitalopram versus venlafaxine). Most studies had methodological or reporting shortcomings (or both): all studies were
at unclear risk of selection and reporting bias. Follow-up rarely extended beyond three months. The lack of adequate power of most of
the studies is also a major concern.
Few studies explored the effect of SSRIs or SNRIs on migraine frequency, the primary endpoint. Two studies with unclear reporting
compared SSRIs and SNRIs to placebo, suggesting a lack of evidence for a difference. Two studies compared SSRIs or SNRIs versus
amitriptyline and found no evidence for a difference in terms of migraine frequency (standardised mean difference (SMD) 0.04, 95%
confidence interval (CI) -0.72 to 0.80; I2 = 72%), or other secondary outcomes such as migraine intensity and duration.
SSRIs or SNRIs were generally more tolerable than tricyclics. However, the two groups did not differ in terms of the number of
participants who withdrew due to adverse advents or for other reasons (one study, odds ratio (OR) 0.39, 95% CI 0.10 to 1.50 and OR
0.42, 95% CI 0.13 to 1.34).
We did not find studies comparing SSRIs or SNRIs with pharmacological treatments other than antidepressants (e.g. antiepileptics and
anti-hypertensives).
Authors’ conclusions
Since the last version of this review, the new included studies have not added high quality evidence to support the use of SSRIs or
venlafaxine as preventive drugs for migraine. There is no evidence to consider SSRIs or venlafaxine as more effective than placebo or
amitriptyline in reducing migraine frequency, intensity, and duration over two to three months of treatment. No reliable information
is available at longer-term follow-up. Our conclusion is that the use of SSRIs and SNRIs for migraine prophylaxis is not supported by
evidence.
P L A I N L A N G U A G E S U M M A R Y
Selective serotonin re-uptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for preventing
migraine
Migraine is a common condition that can significantly impair people’s quality of life. Individuals who experience frequent or severe
migraine may benefit from preventive medications taken prior to an attack and before the pain starts. Studies have suggested the
potential role of neurotransmitters in the genesis of headache. Accordingly, drugs that inhibit the passage of neurotransmitters in brain
cells and, therefore, increase their levels, have been examined for their potential benefit in preventing migraine. Two classes of inhibitors,
the selective serotonin re-uptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), typically used to treat
depression, are evaluated in this review.
This is an update of a previous review that included studies on migraine and tension-type headache. This original review has been split
in two separate reviews: this update addresses only studies on migraine, while a second focuses on tension-type headache. In November
2014, we identified three new studies. Eight studies were already included in the previous version of the review. Overall, we analysed a
total of 585 participants. All the studies had a small number of participants and were conducted over a period of two to three months.
Only a few were of high quality.
The results suggest that SSRIs and SNRIs are no better than placebo (sugar pill) for reducing the number of migraine attacks. There
were no differences in minor side effects between participants treated with SSRIs or SNRIs versus those treated with placebo. SSRIs and
SNRIs seem not to offer advantages when compared to other active treatments, specifically the tricyclic antidepressant amitriptyline.
The participants treated with SSRIs or SNRIs suffered fewer minor side effects than those who took amitriptyline, however the number
of people who stopped taking one drug or the other due to side effects was approximately equal. These results are based on short-term
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trials (no more than three months), which are not properly sized and feature serious methodological deficiencies. We did not find studies
comparing SSRIs or SNRIs with pharmacological treatments other than antidepressants (e.g. antiepileptics and anti-hypertensives).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
SSRIs or SNRIs compared to placebo for migraine prophylaxis in adults
Patient or population: patients for whom migraine preventive interventions are indicated
Intervention: SSRIs or SNRIs
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo SSRIs or SNRIs
Migraine frequency
Number of attacks
Follow-up: 2 to 3 months
See comment See comment - 113
(2 studies)
⊕⊕©©
low1
Studies not pooled, in-
conclusive data
Migraine intensity
Score
Follow-up: 2 to 3 months
See comment See comment - 113
(2 studies)
⊕⊕©©
low1
Studies not pooled, in-
conclusive data
Migraine duration
Hours
Follow-up: 2 to 3 months
See comment See comment - 60
(1 study)
See comment Data reported as median,
no statistically significant
difference
Symptomatic/analgesic
medication use for acute
headache attacks
Follow-up: 2 to 3 months
See comment See comment - 113
(2 studies)
⊕⊕©©
low1
Studies not pooled, in-
conclusive data
Migraine index
Follow-up: mean 2
months
The mean migraine in-
dex ranged across control
groups from
24 to 77.2 points
The mean migraine index
in the intervention groups
was
0.14 SD lower
(0.57 lower to 0.3 higher)
- 86
(3 studies)
⊕©©©
very low2
As a rule of thumb, 0.2 SD
represents a small differ-
ence, 0.5 moderate and
0.8 large (Cohen 1988)
4
S
e
le
c
tiv
e
se
ro
to
n
in
re
u
p
ta
k
e
in
h
ib
ito
rs
(S
S
R
Is)
a
n
d
se
ro
to
n
in
-n
o
re
p
in
e
p
h
rin
e
re
u
p
ta
k
e
in
h
ib
ito
rs
(S
N
R
Is)
fo
r
th
e
p
re
v
e
n
tio
n
o
f
m
ig
ra
in
e
in
a
d
u
lts
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Quality of life See comment See comment Not estimable - See comment Not measured
Withdrawn (due to ad-
verse events)
Study population OR 1.95
(0.70 to 5.44)
221
(5 studies)
⊕©©©
very low2
-
53 per 1000 99 per 1000
(38 to 234)
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio; SD: standard deviation; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Limitations in study design, imprecision (insufficient data).
2Limitations in study design, imprecision (insufficient data), indirectness (lack of generalisability).
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B A C K G R O U N D
This updated systematic review considers the evidence for the effi-
cacy and tolerability of selective serotonin re-uptake inhibitors (SS-
RIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)
for the prevention of migraine. It is an update of a systematic re-
view on SSRIs for the prevention of migraine and tension-type
headache previously published in the Cochrane Database of Sys-
tematic Reviews (Cusi 2000;Moja 2005). Another review is under
development to cover the prevention of tension-type headache (in
press).
Description of the condition
Migraine is a common neurological disorder with episodic man-
ifestations that may persist or progress in frequency over time as
a function of biologic, psychologic, and environmental influences
(Lipton 2004). TheGlobal Burden of Disease Survey 2010 ranked
migraine as the third most prevalent disorder and seventh-highest
specific cause of disability worldwide (Vos 2012). Published esti-
mates of migraine prevalence vary widely, with a lifetime preva-
lence of 20% to 25%; it is reported that 36 million people in the
United States suffer from repeated attacks of migraine (American
Migraine Foundation 2013). However, according to three epi-
demiological studies conducted in the United States, the preva-
lence of migraine is rather stable: migraine occurs in about 12%
of people, with an almost three-fold higher prevalence in adult
women compared to adult men (Buse 2012; Lipton 2001; Steward
1992). An episodic migraine tends to evolve into a chronic form,
often in relation to an overuse of drugs for acute treatment or in
the absence of adequate preventive therapy (Colas 2004;Wiendels
2006). According to a systematic review of population-based stud-
ies the prevalence of chronic migraine is 0% to 5.1%, with esti-
mates typically ranging from 1.4% to 2.2% (Natoli 2010).
Migraine is defined as a recurrent primary headache disorder. Mi-
graine without aura is the most common subtype. It is charac-
terised by attacks lasting four to 72 hours, with a unilateral loca-
tion, pulsating quality, moderate or severe intensity, aggravation
by routine physical activity, and association with nausea and/or
photophobia and phonophobia. Migraine with aura is primar-
ily characterised by focal neurological symptoms that usually pre-
cede or sometimes accompany the headache. The premonitory
phase may occur hours or days before the migraine and includes
symptoms such as hyperactivity, hypoactivity, depression, craving
for particular foods, and repetitive yawning. As one or a few mi-
graine attacks may be difficult to distinguish from symptomatic
migraine-like attacks, at least five attacks are required to confirm
the diagnosis. Migraine frequency is often classified as episodic or
chronic. Chronic migraine occurs when the headache lasts 15 or
more days per month for more than three months, and has the
features of migraine on at least eight days per month. The most
common risk factor for episodic migraine to progress to chronic
migraine is medication overuse (IHS 2013).
Migraine is associated with significant burden, including func-
tional impairment, disability, and reduced quality of life and well-
being (Buse 2012; Steiner 2013; Vos 2012). Costs of the disease
for patients and healthcare systems are also an issue. The substan-
tial economic cost and social impact of migraine has been docu-
mented across diverse settings (Bloudek 2012; Cull 1992; Clarke
1996; Hu 1999; Serrano 2013; Von Korff 1998). The estimates
vary across countries due to differences in available therapies and
they way in which they are delivered, and structural differences
in healthcare systems. A recent cost-of-illness survey conducted as
part of the Eurolight project in six European countries reported
an annual direct and indirect cost of migraine per person of Euro
1222, and a total annual cost for the European countries of Euro
111 billion for adults aged 18 to 65 years (Linde 2012). A survey
conducted in the US reported a similar figure for episodic mi-
graine and costs up to more than USD 7000 for chronic migraine
(Munakata 2009). More than 50% of working persons with mi-
graine report a loss of at least two days of work per month and,
among people with chronicmigraine, a daily use of analgesic drugs
(Zwart 2004).
The recognition of the social and economic burden of migraine
calls for an accurate analysis of the efficacy and safety of preventive
and treatment options currently available, as well as the develop-
ment of new effective strategies.
While migraine is no longer considered a vascular-based phenom-
ena, the pathogenesis is still uncertain. The importance of sensiti-
sation of pain pathways and the possibility that attacks may orig-
inate in the central nervous system have gained increasing atten-
tion over recent decades. Messenger molecules such as nitric oxide
(NO), 5-hydroxytryptamine (5-HT), and calcitonin gene-related
peptide (CGRP) may be involved (Hoffmann 2014). Highly re-
ceptor-specific acute medications such as the triptans have demon-
strated efficacy in the acute treatment of attacks. They have high
receptor specificity, therefore their mechanism of action provides
new insight into migraine mechanisms and it is now clear that
migraine is a neurobiological disorder (IHS 2013).
Description of the intervention
The pharmacological therapy of migraine includes the treatment
of acute attacks, usually using simple analgesics, triptans, and
antiemetics, and a prophylactic approach that aims to reduce the
frequency, severity, and duration of migraine attacks. Preventive
treatment is especially well-suited to patients with very frequent or
severe migraine. It encompasses both episodic and chronic forms,
causing significant headache-related disability, and that are resis-
tant to acute therapy (IHS 2013). For instance, migraine pro-
phylactic therapy can be appropriate if, despite appropriate use
of acute medications and trigger management/lifestyle modifica-
tion strategies, patients still experience attacks that highly affect
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daily activities, or when the frequency of migraine attacks is such
that patients are at risk of medication overuse (rebound) migraine
(Pringsheim 2012).
Although epidemiologic studies suggest that approximately 38%
of migraineurs need preventive therapy, only 3% to 13% cur-
rently use it (Lipton 2007). Several pharmacological strategies
are currently approved or used off-label for migraine prevention
and thought to affect various aspects of migraine pathophysiology
(Sprenger 2009). Preventive treatments aim to eliminate headache
pain without intolerable harms and they are also expected to re-
duce the use of acute drugs and improve quality of life. In clinical
practice the choice of a drug over another is based on many drug-
related factors such as familiarity, efficacy, and adverse effects, as
well as many patient characteristics such as headache frequency,
presence of aura, comorbid conditions, and patient preference.
SSRIs and SNRIs are a class of compounds typically used as an-
tidepressants in the treatment of depression, anxiety disorders, and
some personality disorders. SSRIs increase the extracellular level
of neurotransmitters such as serotonin by inhibiting its reuptake
into the presynaptic cell. Depending on their chemical structure,
these compounds have varying degrees of selectivity for the other
monoamine transporters, with pure SSRIs having only weak affin-
ity for the noradrenaline transporter and non-selective compounds
also blocking the reuptake of noradrenaline and dopamine.
How the intervention might work
The serotonergic system from the brainstem raphe nucleus seems
to be implicated inmigraine pathophysiology. Several studies have
documented a central neurochemical imbalance and changes in
the serotonin metabolism and in the processing of serotonin-me-
diated responses during and in betweenmigraine attacks. How the
abnormal serotonergic neurotransmission is linked to themanifes-
tation of head pain and the accompanying symptoms has yet to be
fully understood. However, evidence suggests that low serotonin
levels facilitate the activation of the trigeminovascular nocicep-
tive pathway, as induced by cortical spreading depression (Hamel
2007).
Similar to migraine, depression is also considered to be a disor-
der of low brain serotonergic activity, and epidemiological studies
have reported comorbidity of migraine with psychiatric disorders
(Buse 2013). Most antidepressant drugs are aimed at enhancing
and stabilising 5-HT neurotransmission and some antidepressants
have been shown to be effective in migraine prophylaxis at lower
doses than those used to treat depression.
In view of the discoveries about the role of serotonin and other
neurotransmitters in pain mechanisms, SSRIs and SNRIs have
also been evaluated for their potential benefit in the treatment of
migraine.
Why it is important to do this review
Clinical guidelines often mention SSRIs and SNRIs as possible
preventive treatments for migraine. However, the role of these
antidepressants for migraine prophylaxis is not completely estab-
lished. The American Society of Internal Medicine recommends
the use of some SSRIs (paroxetine and fluvoxamine) to prevent
migraine, while emphasising that this recommendation is based
on expert consensus and clinical experiences (Snow 2002). Ac-
cording to the American Headache Society (AHS) and the Amer-
ican Academy of Neurology (AAN) data from migraine preven-
tion guidelines to support or refute the use of SSRIs such as flu-
oxetine and fluvoxamine for migraine prophylaxis are insufficient
(Loder 2012). More recent guidelines by the European Federa-
tion of Neurological Societies and Canadian Headache Society do
not consider venlafaxine and other antidepressant drugs as effec-
tive treatments for migraine prophylaxis (Evers 2009; Pringsheim
2012).
O B J E C T I V E S
To determine the efficacy and tolerability of SSRIs and SNRIs
compared to placebo and other active interventions in the preven-
tion of episodic and chronic migraine in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of SSRIs or SNRIs taken
regularly to prevent the occurrence of migraine attacks, reduce the
intensity of those attacks, or both. We included published and
unpublished trials in any language provided that enough informa-
tion about eligibility was available.
Types of participants
Participants of either sex, aged 18 and older, diagnosed with mi-
graine, both episodic and chronic forms. Migraine diagnoses were
based on the diagnostic criteria of the International Headache
Society (IHS 2013 and its previous editions ICHD-II 2004;
IHS 1988) and the Ad Hoc Committee on the Classification of
Headache (Ad Hoc 1962). Where no such criteria were specified,
the diagnosis of migraine had to be based on at least some of its
distinctive features, (e.g. nausea/vomiting; severe pain; pulsating/
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throbbing pain; mainly unilateral pain; and the presence of pho-
tophobia, phonophobia, and/or aura). Patients with episodic mi-
graine usually have it two to eight times per month. Chronic mi-
graine is defined as that occurring with a frequency of at least 15
days/month (180 days/year) for at least a three-month period.
We included studies in which participants were described as hav-
ing ’combination’ or ’mixed’ migraine and tension-type headaches
only if data on migraine participants could be extracted. We ex-
cluded trials including patients with a secondary headache.
Types of interventions
To be considered for inclusion, trials were required to have at
least one treatment arm in which patients were treated with one
of the SSRIs or SNRIs commercially available or under develop-
ment (fluoxetine, paroxetine, fluvoxamine, citalopram, escitalo-
pram, milnacipran, sertraline, venlafaxine, desvenlafaxine, dulox-
etine, dapoxetine). We considered any dosage or any dosing regi-
men lasting for at least four weeks. Acceptable comparator groups
included placebo, no intervention, other drug treatments, and be-
havioural or physical therapies. It was expected that patients were
free to takemedication for acute migraine attacks as needed during
the trial period.
Types of outcome measures
In this update, we reconsidered the outcome measures, taking
into consideration patients’ preferences, scientific rigour, and the
availability of data. In line with the guidelines for controlled trials
of drugs in migraine issued by the IHS (Tfelt-Hansen 2012), the
main outcomes to be considered were:
Primary outcomes
• Migraine frequency.
We considered the following ways of measuring migraine fre-
quency, listed in the preferred order:
• number of migraine attacks per evaluation period;
• number of days with migraine per evaluation period;
• responders, i.e. patients with ≥ 50% reduction in headache
frequency.
Secondary outcomes
• Migraine intensity, measured using a numerical or verbal
scale.
• Migraine duration (hours).
• Symptomatic/analgesic medication use for migraine attacks.
• Migraine index: we preferred those that incorporated
frequency as a component (along with intensity and/or
duration), but considered other types of indexes when these were
not available. The formula used to calculate the headache index
is recorded in the text below and in the table describing the
Characteristics of included studies whenever it was reported by
investigators.
• Quality of life, measured using validated instruments.
• Withdrawals (for any reasons and due to adverse events).
• Minor adverse events.
We sought migraine-associated symptoms (nausea, photophobia,
phonophobia) and other outcome measures (e.g. workdays lost,
mood improvement, and cost-effectiveness).
We initially recorded the outcomes for all of the assessment peri-
ods reported, then, once all of the data had been collected, decided
upon which time points to consider in the analysis: we preferred
the last periods of the follow-up, usually eight and 12 weeks. The
analyses considered only outcomes obtained directly from the pa-
tient, excluding those judged by the treating physician or study
personnel.
We included the following outcome measures in the ’Summary
of findings’ table (Summary of findings for the main comparison;
Summary of findings 2).
1. Migraine frequency.
2. Migraine intensity.
3. Migraine duration.
4. Symptomatic/analgesic medication use for migraine attacks.
5. Migraine index.
6. Quality of life.
7. Withdrawals due to adverse events.
Search methods for identification of studies
The search strategies used for this review are common to a review
on SSRIs and SNRIs for tension-type headache prophylaxis in
adults (in press).
Electronic searches
For the original review, we searched MEDLINE (1966 to Jan-
uary 2004), EMBASE (1994 to May 2003), the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL 2003, Issue 4),
andHeadache Quarterly (1990 to 2003). For this update, we ap-
plied a revised search strategy to reflect the broader type of in-
tervention (SSRIs and SNRIs). We searched CENTRAL (2014,
Issue 10), MEDLINE (1946 to November 2014), EMBASE
(1980 to November 2014), and PsycINFO (1987 to Novem-
ber 2014). We also searched trial registries (the metaRegister
of Controlled Trials (mRCT) (www.controlled-trials.com/mrct),
clinicaltrials.gov, and the World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP) (http:/
/apps.who.int/trialsearch/) for ongoing trials (November 2014).
Details of the search strategies are provided in Appendix 1.
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Searching other resources
Additional strategies for identifying trials included searching the
reference lists of review articles and included studies, search-
ing books related to headache, consulting experts in the field of
headache, contacting the authors of trial reports, and contacting
pharmaceutical companies to identify additional published or un-
published data.
Data collection and analysis
Compared to the previous version of the review, we revised the
assessment of methodological quality of the included trials to in-
clude the most recent ’Risk of bias’ approach (Assessment of risk
of bias in included studies).
Selection of studies
Two review authors independently screened titles and abstracts
from the search and judged whether trials fulfilled the inclusion or
exclusion criteria. We resolved disagreements through discussion
with a third author and by contacting the study authors, if needed.
Review authorswere not blinded to the names of the study authors,
their institutions, the journal of publication, or the results. We
retrieved all potentially relevant articles for the assessment of the
full publication.
Data extraction and management
Two authors independently abstracted information on study
methods (design, duration, randomisation, blinding, with-
drawals), participants (age, sex, type of headache, duration of dis-
ease, co-existing depression and other psychiatric illnesses, and
concomitant drugs), interventions (type of drug, route of adminis-
tration, and dosage), outcomes, and adverse events using specially
designed, pre-tested, electronic extraction forms. We resolved dis-
agreements through discussion with a third author. We entered
data into Review Manager for analysis (RevMan 2014).
When outcomes were reported in dichotomous form (success/
failure), we required that the threshold for distinguishing between
success and failure be clinically significant (for instance, more than
a 50% reduction in frequency or intensity).
When outcome data were reported on an ordinal scale, we se-
lected a threshold based on the definition of clinically significant
improvement and converted the data into a dichotomous form.
If categorical data could not be split into dichotomous outcomes
meeting our a priori definition, we did not include the data in the
analysis.
When a trial used pre- and post-treatment scores to calculate a
change score for each patient, and then used these within-patient
change scores to calculate a group mean change score, we recorded
and analysed the group mean change scores. When only post-
treatment data were available, we used these, relying on allocation
to achieve between-group balance.
Assessment of risk of bias in included studies
Two review authors assessed the risk of bias for each of the included
studies using the ’Risk of bias’ tool developed by The Cochrane
Collaboration (Higgins 2011). This includes five domains of bias:
selection, performance, attrition, detection and reporting, as well
as an ’other bias’ category to capture other potential threats to
validity.
Selection bias included an assessment of adequate sequence gener-
ation as well as allocation concealment.We assessed sequence gen-
eration to be at low risk when studies clearly specified amethod for
generating a truly random sequence. We assessed allocation con-
cealment to be at low risk if the method used to ensure that inves-
tigators enrolling participants could not predict group assignment
was described. Performance and detection bias were incorporated
under the blinding domain in the ’Risk of bias’ tool: we did not
consider them separately as the large majority of outcomes were
self reported by the patients (i.e. using diaries). We assessed this to
be low risk for studies that reported blinding of participants and
study personnel. We assessed studies as low risk for attrition bias if
an adequate description of participant flow through the study was
provided, the proportion of missing outcome data was relatively
balanced across groups, and the reasons for missing outcome data
were provided, relatively balanced between groups, and considered
unlikely to bias the results.
We assessed studies as having low risk of reporting bias when a
published protocol was available and all specified outcomes were
included in the study report; we assessed studies without a pub-
lished protocol as unclear. When an outcome measure was speci-
fied and the results were not reported either at baseline or at fol-
low-up, we considered the study to be at high risk of reporting
bias.
We assessed other potential threats to validity, including early trial
discontinuation for benefit and trial sponsorship.
Review authors were not blinded with respect to study authors,
institution, or journal. We resolved disagreements through discus-
sion with a third author.
Measures of treatment effect
In order to assess efficacy, we extracted raw data for outcomes of
interest (means and standard deviations for continuous outcomes
and number of events for dichotomous outcomes) when available
in the published reports.
For dichotomous outcomes, we calculated odds ratios (ORs) along
with 95% confidence intervals. Where outcomes were measured
on standard scales, we calculated mean differences (MDs). Where
different scales were used tomeasure the same or similar outcomes,
we calculated standardised mean differences (SMDs).
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We calculated numbers needed to treat to benefit (NNTB) if possi-
ble, although this was a rare circumstance due to the large number
of statistically insignificant comparisons. We analysed toxicity for
total withdrawals due to adverse events. We calculated numbers
needed to treat to harm (NNTH) if possible.
Unit of analysis issues
Cross-over trials
In randomised cross-over studies, individuals receive each inter-
vention sequentially in a random order. Cross-over studies usually
contain a washout period, which is a stage after the first treatment
but before the second treatment, where time is given for the active
effects of the first treatment to wear off before the new treatment
begins (that is to reduce the carryover effect). A concern with the
cross-over design is the risk of a carryover effect when the first
treatment affects the second. Inadequate washouts are seen when
the carryover effect exceeds the washout period. For this review,
we considered an adequate washout period for cross-over studies
to be a minimum of one week. When including cross-over studies
with an inadequate washout period we used only the first armdata.
Even though this method does not consider all of the information
provided it avoids inappropriate consideration of correlated infor-
mation.
Cluster trials
We assessed whether the unit of analysis was appropriate for the
unit of randomisation. If we were to include cluster-RCTs, we
would use the intra-class correlation coefficient (ICC) to convert
trials to their effective sample size before incorporating them into
the meta-analysis.
Dealing with missing data
We described missing data and the drop-outs/attrition from each
included study in the Characteristics of included studies. We
planned the analysis of outcomes on an intention-to-treat basis;
in other words, we included all of the participants randomised
to each group in the analyses, regardless of whether or not they
received the allocated intervention, and irrespective of how the
original study authors analysed the data. However, because only
a few studies reported the needed data, we analysed the studies
according to an ’available case’ approach.
We contacted study authors by email to clarify any missing data.
For outcomes reported on a continuous scale, we anticipated that
many trials would report pre- and post-treatment group means
without reporting data on the variance associated with these
means. We attempted to calculate or estimate variances based on
primary data or test statistics whenever precise P values or test
statistics were provided in sufficient detail.
Assessment of heterogeneity
We assessed statistical heterogeneity by examining the I2 statistic
(Deeks 2011), a quantity that describes the proportion of variation
in point estimates that is due to variability across studies rather
than sampling error.
We interpreted the I2 statistic as suggested by the latest version of
Higgins 2011:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
In addition, we used a Chi2 test of homogeneity to determine the
strength of evidence that heterogeneity is genuine.
We explored clinical variation across studies by comparing the dis-
tribution of important participant factors among trials (for exam-
ple, age) and trial factors (randomisation concealment, blinding
of outcome assessment, losses to follow-up, treatment type, and
co-interventions).
Data synthesis
We performed the analyses using Review Manager (RevMan
2014). We assumed a considerable clinical heterogeneity and usu-
ally combined the studies using the random-effects model. When
including both parallel and cross-over studies with an adequate
washout period, we used the inverse variance method, as recom-
mended by Elbourne 2002. In the meta-analysis, the weight of
each study is inversely proportional to the variance (one over the
square of the standard error) (Deeks 2011).
’Summary of findings’ table
We synthesised the main outcome measures (see also Types of
outcome measures) in two ’Summary of findings’ tables, compar-
ing SSRIs or SNRIs to placebo (Summary of findings for the main
comparison) or to other active comparators (Summary of findings
2).Whenever possible, we used the control arm to calculate the ’as-
sumed risk’ values. We assessed the overall quality of the evidence
for each outcome using the GRADE approach, as recommended
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), against five factors: study design and limitations,
consistency of results, directness (generalisability), precision (suf-
ficient data), and reporting of the results across all studies that
measure that particular outcome. The quality starts at high when
high quality RCTs provide results for the outcome, and reduces
by a level for each of the factors not met.
• High quality evidence: there are consistent findings among
at least 75% of RCTs with no limitations of the study design,
consistent, direct and precise data, and no known or suspected
publication biases. Further research is unlikely to change either
the estimate or our confidence in the results.
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• Moderate quality evidence: one of the domains is not met.
Further research is likely to have an important impact on our
confidence in the estimate of effect and may change the estimate.
• Low quality evidence: two of the domains are not met.
Further research is very likely to have an important impact on
our confidence in the estimate of effect and is likely to change
the estimate.
• Very low quality evidence: three of the domains are not
met. We are very uncertain about the results.
• No evidence: no RCTs were identified that addressed this
outcome.
Subgroup analysis and investigation of heterogeneity
We investigated the effects in two subgroup analyses:
• Trials in which patients were depressed (as determined by a
rating scale or clinical interview) versus trials in which patients
were not depressed.
• Trials evaluating the various SSRIs and SNRIs separately.
Sensitivity analysis
We did not plan any sensitivity analysis.
R E S U L T S
Description of studies
Results of the search
The new electronic search up to November 2014 retrieved a total
of 4508 results after discarding duplicates. After retrieving full-text
articles, we included three new studies (253 participants) (Bulut
2004; Ozyalcin 2005; Tarlaci 2009), along with the eight studies
already included.We classified three studies, whichwere published
only as poster presentations (Dzagnidze 2009; Stanic 2009; Togha
2014), and one Chinese publication (He 2004), as awaiting classi-
fication (see Characteristics of studies awaiting classification). Af-
ter searching clinical trial registries, we found four ongoing stud-
ies that were potentially eligible: two on duloxetine and two on
milnacipran. Of these, we excluded three because they were not
controlled trials, while we classified one assessing the efficacy of
milnacipran in headache pain reduction in patients with chronic
migraine without fibromyalgia as ’ongoing’ (see Characteristics of
ongoing studies).
See Figure 1.
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Figure 1. PRISMA flow diagram
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Included studies
Overall, we included 11 studies published between 1991 and
2009 in this updated review (Adly 1992; Bank 1994; Bulut 2004;
Colucci d’Amato 1999a; Krymchantowski 2002; Landy 1999;
Oguzhanoglu 1999; Ozyalcin 2005; Polisca 1992; Steiner 1998;
Tarlaci 2009).
All but one, Bulut 2004, were parallel studies. Steiner 1998 was a
multicentre trial. The mean length of studies was 13 weeks (range:
eight to 24 weeks).
A description of an initial run-inwashout period from the previous
preventive drug was given in six studies (Adly 1992; Bank 1994;
Bulut 2004; Colucci d’Amato 1999a; Landy 1999; Steiner 1998).
See Characteristics of included studies.
Participants
The included studies enrolled a total of 585 participants, with
womenmore represented thanmen (73% versus 27%). Four stud-
ies did not report the sex of non-completers (Adly 1992; Bulut
2004; Oguzhanoglu 1999; Tarlaci 2009). The mean age of the pa-
tients ranged from 31 (Tarlaci 2009) to 43.5 (Polisca 1992) years
old.
Eight studies (N = 461) enrolled patients with migraine mainly di-
agnosed following the IHS classification (Adly 1992; Bank 1994;
Bulut 2004;Colucci d’Amato 1999a; Landy 1999;Ozyalcin 2005;
Steiner 1998; Tarlaci 2009). One (N = 39) included patients
with migraine transformed into chronic daily headache due to
symptomatic medication overuse (Krymchantowski 2002) and
one (N = 60) with chronic daily headache caused by underly-
ing chronic migraine, with episodic tension-type attacks (Polisca
1992). One study included a mixed population, e.g. patients with
migraine, chronic tension-type headache, and episodic tension-
type headache (Oguzhanoglu 1999, N = 52).
One study included depressed patients (Adly 1992), while in two
other studies depressed patients were clearly excluded (Bulut 2004;
Oguzhanoglu 1999). The remaining studies excluded patients suf-
fering from generic neurological or psychiatric conditions, or on
treatment with antidepressant drugs.
The median number of patients randomised in the included stud-
ies was 53 and ranged from 27 (Landy 1999) to 105 (Tarlaci
2009). Losses to follow-up were greater than 30% in three studies
(Bulut 2004; Krymchantowski 2002; Steiner 1998) and greater
than 40% in two (Adly 1992; Landy 1999).
Interventions and controls
Five studies compared SSRIs with placebo (fluoxetine four stud-
ies: Adly 1992; Colucci d’Amato 1999a; Polisca 1992; Steiner
1998; sertraline one study: Landy 1999). Two studies compared
SSRIs (fluoxetine one study: Oguzhanoglu 1999; fluvoxamine
one study: Bank 1994) with amitriptyline. Krymchantowski 2002
compared a regime of fluoxetine plus amitriptyline with amitripty-
line alone. Three studies compared SNRIs (venlafaxine) with
placebo (Ozyalcin 2005), amitriptyline (Bulut 2004), and esci-
talopram (Tarlaci 2009), respectively.
Four studies used a fixed dose of fluoxetine (20 mg or 40 mg
daily) (Colucci d’Amato 1999a;Oguzhanoglu 1999; Polisca 1992;
Steiner 1998), while in two trials dose ranged up to 40 mg/day
(Adly 1992; Krymchantowski 2002). Similarly, one study used
fixed doses of venlafaxine (75 mg/day or 150 mg/day) (Ozyalcin
2005), while two used dose escalations from 37.5 mg/day to 150
mg/day (Bulut 2004;Tarlaci 2009). In the active comparator trials,
amitriptyline was increased progressively over the first two weeks
of treatment.
For the other SSRIs the average doses were: sertraline 50 mg/day
(Landy 1999), and fluvoxamine 50 mg/day (Bank 1994).
We did not identify any study comparing SSRIs or SNRIs with a
drug treatment other than antidepressants or with a non-pharma-
cological treatment (behavioural or physical therapy).
Country and language of publication
Four studieswere carried out inTurkey (Bulut 2004;Oguzhanoglu
1999;Ozyalcin2005;Tarlaci 2009), two in Italy (Colucci d’Amato
1999a; Polisca 1992), two in the US (Adly 1992; Landy 1999),
and one each in Brazil (Krymchantowski 2002), Hungary (Bank
1994), and theUK (Steiner 1998). The only non-English language
paper included was published in Italian (Polisca 1992).
Excluded studies
In the original review, we excluded nine studies because they were
not randomised, four because the license of the SSRI studied
(femoxetine) has been discontinued by drug companies (com-
pany communication, Knoll, February 1988, and Martec, Febru-
ary 1990). In the original review, we excluded two studies be-
cause it was impossible to separate data on patients with migraine
from data on patients with chronic daily headache or chronic ten-
sion-type headache (Bussone 1991; Saper 1994). We contacted
the authors, who confirmed that study data and analyses are no
longer available. In this update, we excluded one study because it
recruited patients with comorbidity of depression, migraine, and
tension-type headache (Rampello 2004). We excluded one trial
previously classified as ’awaiting for classification’ as it did not re-
port any comparison between treatment groups (Amelin 2000).
We also excluded one trial among those screened in this update as
both groups were treated with venlafaxine (Centonze 2000).
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See Characteristics of excluded studies and Figure 1.
Risk of bias in included studies
The overall risk of bias is presented graphically inFigure 2 and sum-
marised in Figure 3. The majority of included trials had method-
ological or reporting shortcomings, or both. We cannot exclude
the fact that poor reporting could have hampered our assessment.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
None of the included studies reported information on how the
random sequence was generated and concealed from the study
personnel.
Blinding
Five studies were double-blind and reported information on how
participants or physicians, or both, were blinded to the study treat-
ments (Bulut 2004; Colucci d’Amato 1999a; Krymchantowski
2002; Landy 1999; Steiner 1998). Four trials were claimed to be
double-blinded but no additional information was reported (Adly
1992; Bank 1994; Ozyalcin 2005; Polisca 1992). One study did
not report any information on blinding (Tarlaci 2009), and one
was open-label (Oguzhanoglu 1999).
Incomplete outcome data
We judged four studies at low risk of attrition bias (Colucci
d’Amato 1999a; Krymchantowski 2002; Ozyalcin 2005; Polisca
1992), and four at high risk: Adly 1992 and Landy 1999 due to a
high drop-out rate (more than 40% lost at follow-up); Bank 1994
and Tarlaci 2009 due to a moderate drop-out rate but imbalanced
among arms and with reasons for drop-out not fully reported. We
judged the remaining three studies at unclear risk of bias as we
did not have sufficient information on drop-outs (Bulut 2004;
Oguzhanoglu 1999; Steiner 1998).
Selective reporting
We did not find any information useful to assess the possible selec-
tive reporting of studies and outcomes. None of the trials included
in this version of the review are registered nor have a publicly avail-
able protocol for consultation. All the studies used multiple out-
comes without a predefined primary outcome and multiple time
points for the assessment. This suggests possible selective outcome
reporting.
Other potential sources of bias
Seven studies did not provide any information about finan-
cial sponsorship (Adly 1992; Bank 1994; Bulut 2004; Colucci
d’Amato 1999a; Oguzhanoglu 1999; Polisca 1992; Tarlaci 2009).
Two were supported by the manufacturer of the SSRI or SNRI
being tested (Ozyalcin 2005; Steiner 1998), one by a charitable
organisation (Landy 1999), and one was apparently without any
financial or other type of support (Krymchantowski 2002).
We have particular doubts about one study, which reported ex-
tremely positive results in favour of fluoxetine but was charac-
terised by a general lack of detail in reporting (Polisca 1992). Our
concerns include the following: (1) lack of any clear evidence that
the patients were truly randomised; (2) 100% of patients (N =
60) completed the study; (3) the adopted statistical analysis is in-
sufficiently described; and (4) identical means and standard de-
viations are reported for two different outcomes (frequency and
symptomatic/analgesic medication use).
Only one study reported an adequate sample size calculation (
Steiner 1998), with most of the studies clearly underpowered and,
therefore, more prone to be inconclusive (e.g. not enabled to find
a statistically significant difference that is true) (Altman 1990;
Hotopf 1997; Hotopf 1999). The median sample size was 53 and
ranged from 27 to 105. The mean drop-out rate was 22% of all
randomised patients, leading to much smaller sample size across
studies.
With respect to the previous version of this review, the median
sample size per arm increased by 20% (from 25 to 30). However,
concerns remain about the fact that many studies are likely to be
underpowered to detect any difference (Moja 2005).
The lack of statistical power is reflected in the use of a large number
of rating scales to measure outcomes. Furthermore the majority
of trials analysed the multiple outcomes at many different time
intervals (four weeks, eight weeks, etc.), increasing exponentially
the number of comparisons. Performing multiple comparisons
easily leads to detect statistically significant differences that are
spurious (Thornley 1998).
Only one trial stated that the analysis was done by intention-to-
treat but no additional details were provided (Tarlaci 2009). The
number of patients in the final analysis (when reported) rarely
matched that which was reported at baseline. Only two studies
analysed the patients on the basis of the randomised group, but
this was related to the fact that there were no drop-outs (Colucci
d’Amato 1999a; Polisca 1992).
Effects of interventions
See: Summary of findings for the main comparison SSRIs
or SNRIs compared to placebo for migraine prevention in
adults; Summary of findings 2 SSRIs or SNRIs compared to
amitriptyline for migraine prevention
Whenever possible, for each efficacy outcome, we focused on out-
comes at two different follow-up time points in the same analysis
graph (eight and 12 weeks).
SSRIs or SNRIs versus placebo
None of the new trials included in this update compared SSRIs
to placebo. One study compared venlafaxine, 75 mg or 150 mg
administered once a day, to placebo (Ozyalcin 2005). This study
reported variables as medians (e.g. number of days with migraine)
while other outcomes were reported with categorical data (e.g.
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daily activities deteriorated, remainedunchanged, improved).One
study reported continuous data on several efficacy outcomes, but
did not report variance data (Steiner 1998). We contacted the au-
thors to obtain the missing data, however we did not receive any
additional information. Due to incomplete reporting and other
shortcomings, these two trials could not be pooled in meta-anal-
yses.
Primary outcome
Migraine frequency
Steiner 1998 assessed changes from baseline in both (i) number
of attacks and (ii) number of days with migraine per month. For
number of attacks, there was no significant difference between
fluoxetine and placebo after two months of treatment: mean fre-
quency decreased from 3.3 to 1.8 with fluoxetine, and from 4.1 to
2.4 with placebo (no F or P values reported). After three months
of treatment, the mean frequency was 1.6 attacks in the fluoxe-
tine group compared to 3.0 in the placebo group (F value = 4.55;
P value = 0.041). The mean number of days with migraine per
month decreased from 7.2 to 4.1 with fluoxetine, and from 8.8 to
6.6 with placebo (no F or P values reported).
Ozyalcin 2005 reported that the number of days with migraine
was reduced only by venlafaxine 150 mg (median over placebo:
four days less per month).
Secondary outcomes
Migraine intensity
Steiner 1998 reported results for this outcome. Investigators used
a three-point scale (1 = mild, 2 = moderate, 3 = severe) and a
Patient’s Global Impression of Disease Severity scale (100 mm
visual analogue scale) to measure headache intensity. After three
months of treatment, there was no significant difference between
the two groups on the three-point scale (mean scores at baseline
and three months: 1.7 and 1.9 with fluoxetine, 1.7 and 1.7 with
placebo). The Patient’s Global Impression of Disease Severity scale
score decreased with fluoxetine at two months (F value = 5.75; P
value = 0.033) and threemonths (F value = 3.83; P value = 0.060).
Ozyalcin 2005 did not find any difference in terms of pain in-
tensity among the three groups (venlafaxine 75 mg or 150 mg, or
placebo).
Migraine duration
OnlyOzyalcin2005 reported data on this outcome.This study did
not find any statistically significant difference in terms of migraine
duration among the three groups (venlafaxine 75 mg, 150 mg, or
placebo).
Symptomatic/analgesic medication use
Steiner 1998 reported that the mean number of doses taken per
attack increased slightly from baseline to three months in both
groups, from 2.4 to 2.9 with fluoxetine, and from 2.0 to 2.3
with placebo. There was no significant difference between the two
groups (no F or P values reported).
Ozyalcin 2005 reported a “statistically significant decrease” in anal-
gesic drug consumption (median decrease of five units, venlafax-
ine 150 mg over placebo
Migraine index
Three trials provided data in an unambiguous format (Adly 1992;
Colucci d’Amato 1999a; Landy 1999). Adly 1992 utilised a mi-
graine score, based on patient diaries, which combined a subjective
record of intensity, duration of migraine, and amount of medica-
tion used to abort the attack. Colucci d’Amato 1999a and Landy
1999 calculated a migraine index combining levels of pain inten-
sity and duration of pain in each level.
SSRIs did not improve the migraine score at eight weeks (three
studies, N = 86) compared to placebo. The combined standardised
mean difference (SMD) was -0.14 (95% confidence interval (CI)
-0.57 to 0.30; I2 = 0%), which is not statistically significant. One
study, Colucci d’Amato 1999a, also reported data at 12 weeks: the
SMD was -0.32 (95% CI -0.88 to 0.25) (Analysis 1.1; Figure 4).
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Figure 4. Forest plot of comparison: 1 SSRI or SNRI versus placebo, outcome: 1.1 Migraine index.
Quality of life
None of the included studies reported data on quality of life.
Withdrawals (for any reasons and due to adverse events)
Overall, similar rates of withdrawals were found in the five studies
where patients were treated with SSRI or SNRI (N = 127) or
placebo (N = 94). We found no significant difference between the
two treatments (Peto odds ratio (OR) 1.37, 95% CI 0.73 to 2.56;
I2 = 0%) in terms of the number of patients who withdrew from
treatment for any reason (Analysis 1.2).
Of patients receiving a SSRI or SNRI, 9.4% (12/127) withdrew
from treatment due to adverse events, compared with 5.3% (5/
94) of patients treated with placebo (Peto OR 1.95, 95% CI 0.70
to 5.44; I2 = 0%) (Analysis 1.3; Figure 5).
Figure 5. Forest plot of comparison: 1 SSRI or SNRI versus placebo, outcome: 1.3 Withdrawals due to
adverse events.
Minor adverse events
The number of patients with minor adverse effects was reported in
two studies (Adly 1992; Colucci d’Amato 1999a). In Adly 1992,
3/16patients treatedwith fluoxetine and 3/16 treatedwith placebo
experienced minor adverse events (fluoxetine: insomnia and anxi-
ety, strange skin sensations, excitement and insomnia; placebo: in-
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somnia and anxiety, weakness, and problems sleeping). In Colucci
d’Amato 1999a, 8/32 patients taking fluoxetine and 3/20 patients
on placebo reported minor adverse events (fluoxetine: pyrosis, as-
thenia, excitement, insomnia; placebo: asthenia, sleepiness). There
was no significant difference between the two treatments (OR
1.46, 95% CI 0.47 to 4.52; Analysis 1.4).
SSRIs and SNRIs versus another active drug
(amitriptyline)
Two studies compared a SSRI (fluoxetine, fluvoxamine) to
amitriptyline in patients withmigraine (Bank 1994; Oguzhanoglu
1999). Oguzhanoglu 1999 did not report any quantitative data
that could be used in our analyses.
One cross-over study compared different regimens of venlafaxine
to amitriptyline (Bulut 2004). We included data on migraine at-
tacks, duration, and intensity considering the first period only.
Primary outcome
Migraine frequency
Bank 1994 used a frequencymeasure called theHeadache Unit In-
dex (HUI), defined as the number of migraine attacks divided by
the number of days in the visit period. The author presented only
within-group analyses and reported that the HUI decreased from
baseline to the end of treatment (three months). Bulut 2004 re-
ported the number of attacks per month at four and threemonths,
respectively. No significant difference between SSRI or SNRI and
amitriptyline was found (SMD 0.04, 95% CI -0.72 to 0.80; I2 =
72% Analysis 2.1; Figure 6). Oguzhanoglu 1999 described only
within-group analyses and reported no quantitative data. The in-
vestigators stated that no significant reduction was found in mi-
graine frequency (number of days with headache per month) at
three months in migraine patients (N = 15) receiving either flu-
oxetine or amitriptyline.
Figure 6. Forest plot of comparison: 2 SSRI or SNRI versus another active drug (amitriptyline), outcome:
2.1 Migraine frequency (number of migraine attacks).
Secondary outcomes
Migraine intensity
This outcome was considered by Bulut 2004 and Oguzhanoglu
1999. Bulut 2004 used a 0- to 3-point scale, where 0 = able towork
throughout the attack and 3 = staying in bed. Venlafaxine and
amitriptyline were similar in reducing migraine intensity (mean
difference (MD) 0.52, 95%CI -0.04 to 1.07). Oguzhanoglu 1999
did not report quantitative data but stated that neither fluoxetine
nor amitriptyline significantly reduced migraine intensity over the
three-month treatment period; there was no clear definition of the
intensity measure used.
Migraine duration
This outcome was considered by Bulut 2004 and Oguzhanoglu
1999. Bulut 2004 reported that venlafaxine and amitriptyline were
similar in reducing migraine duration (MD 1.41, 95% CI -0.03
to 2.85). Oguzhanoglu 1999 did not report quantitative data but
stated that fluoxetine reduced attack duration at two months (P
value = 0.015) and at three months (P value = 0.013). No signifi-
cant differences were found within the amitriptyline group.
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Symptomatic/analgesic medication use
None of the included studies reported data on symptomatic/anal-
gesic medication use.
Migraine index
Bank 1994 provided data using two different indexes and we pre-
ferred the one that incorporated frequency. This was called the
Headache Index (HI) and was defined as the number of migraine
attacks times the intensity of attacks (mild, moderate, or severe)
divided by the number of days in the visit period. The author
presented only within-group analyses and reported that the HI
decreased from baseline to the end of treatment (three months)
with both fluvoxamine and amitriptyline.
Withdrawals (for any reasons and due to adverse events)
Oguzhanoglu 1999 reported two drop-outs but did not specify
their treatment group. Bank 1994 reported that 15.6% (5/32) of
patients receiving fluvoxamine withdrew from treatment, com-
pared with 31.3% (10/32) of patients treated with amitriptyline;
the difference between the two treatments was not statistically sig-
nificant (Peto OR 0.42, 95% CI 0.13 to 1.34).
In Bank 1994, 9.4% of patients receiving fluvoxamine (3/32)
withdrew from treatment due to adverse events, compared to
21.9% of patients treated with amitriptyline (7/32). The differ-
ence was not statistically significant (Peto OR 0.39, 95% CI 0.10
to 1.50). Bulut 2004 reported drop-out for both periods together:
five (8.6%) patients withdrew from treatment due to hypersom-
nia in the amitriptyline group and one (1.7%) due to nausea and
vomiting in the venlafaxine group. Reasons for withdrawals are
specified in the Characteristics of included studies.
Minor adverse events
Oguzhanoglu 1999 reported only aggregated data on adverse
events. In Bank 1994, 12.5% of patients treated with fluvoxam-
ine (4/32) experienced drowsiness, dry mouth, nausea, or gen-
eral weakness during the first week; 15.6% of patients receiving
amitriptyline (5/32) experienced drowsiness. The difference be-
tween the two treatmentswas not statistically significant (OR0.77,
95% CI 0.19 to 3.18).
Chronic daily headache
In this section, we reported the results of two studies that included
participants with chronic daily headache or transformed migraine
(Krymchantowski 2002; Polisca 1992). These definitions are no
longer used in clinical practice and, in fact, we found no new
studies. Furthermore, the rigour of the study design was far from
optimal. The findings of this section are likely to be of little rel-
evance and are no longer reported in this update (for details see
Moja 2005).
Polisca 1992 described the headache syndrome of included pa-
tients with a chronic type of migraine with tension-type episodes,
and compared fluoxetine versus placebo. We have major concerns
about the methodological quality of this study. This study re-
ported that fluoxetine was more effective than placebo in terms of
headache frequency, headache index, and symptomatic/analgesic
medication use after eight and 12 weeks of follow-up. No drop-
outs were observed and no adverse events reported.
Krymchantowski 2002 included participants suffering from trans-
formed migraine with symptomatic medication overuse treated
with fluoxetine and amitriptyline or amitriptyline alone. No dif-
ference in terms of headache index, total withdrawals, and with-
drawals due to adverse events were reported.
Planned subgroup analyses
Only Adly 1992 included patients with depression, thus we lacked
sufficient data to compare trials enrolling depressed patients versus
trials in which patients were not depressed.
Due to the low number of trials included we could not analyse the
various SSRIs and SNRIs separately.
Prevention of transformation to a chronic headache
syndrome
We did not find trials focusing on whether SSRIs or SNRIs could
prevent the progression of an episodic migraine into a chronic
headache syndrome.
Head-to-head comparison
One study compared escitalopram to venlafaxine, a serotonin and
weak nor-adrenaline reuptake inhibitor in 93 patients with mi-
graine without depression or anxiety (Tarlaci 2009). The authors
described mainly within-group analyses and did not report a sta-
tistical comparison between two tested drugs. Venlafaxine and es-
citalopram appear to have similar efficacy in terms of migraine
frequency (5.1 versus 6.6 attack/months) and migraine duration
(6.7 versus 4.6 hours), while escitalopram appears to have a better
safety profile.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
SSRIs or SNRIs compared to amitriptyline for migraine prophylaxis in adults
Patient or population: patients for whom migraine preventive interventions are indicated
Intervention: SSRIs or SNRIs
Comparison: amitriptyline
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Amitriptyline SSRIs or SNRIs
Migraine frequency
Number of attacks
Follow-up: 3 to 4 months
The mean migraine fre-
quency ranged across
control groups from
0.09 to 1.23 number of
attacks
The mean migraine fre-
quency in the intervention
groups was
0.04 SD higher
(0.72 lower to 0.80
higher)
- 96
(2 studies)
⊕©©©
very low1
As a rule of thumb, 0.2 SD
represents a small differ-
ence, 0.5 moderate and
0.8 large (Cohen 1988)
Migraine intensity
Score
Follow-up: 3 to 4 months
See comment See comment - 104
(2 studies)
⊕⊕©©
low2
Studies not pooled, in-
conclusive data
Migraine duration
Hours
Follow-up: 3 to 4 months
See comment See comment - 104
(2 studies)
⊕⊕©©
low2
Studies not pooled, in-
conclusive data
Symptomatic/analgesic
medication use for acute
headache attacks
See comment See comment Not estimable - See comment Not measured
Migraine index
Score
Follow-up: 3 months
See comment See comment Not estimable 62
(1 study)
⊕©©©
very low3
Reported only within-
group analyses
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Quality of life See comment See comment Not estimable - See comment Not measured
Withdrawn (for any rea-
sons and due to adverse
events)
Study population OR 0.39
(0.1 to 1.50)
64
(1 study)
⊕⊕©©
low2
-
219 per 1000 98 per 1000
(27 to 296)
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio; SD: standard deviation; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Limitations in study design, imprecision (insufficient data), inconsistency (heterogeneity).
2Limitations in study design, imprecision (insufficient data).
3Limitations in study design, imprecision (insufficient data), indirectness (lack of generalisability).
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D I S C U S S I O N
Summary of main results
Evidence supporting the use of selective serotonin reuptake in-
hibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors
(SNRIs) to ameliorate the most relevant clinical outcome in adult
patients with migraine - frequency - is scarce. The only new study
included in this update that analysed a SNRI, venlafaxine, versus
placebo, reported a decrease of migraine frequency. However, it is
questionable to rely on the evidence originated by a single spon-
sored study with poor reporting. SSRIs and SNRIs may be useful,
not useful, or detrimental for attacks of migraine. Our analysis
does not exclude any of these possibilities. However, the interpre-
tation most likely to emerge in revising all the evidence is that,
when compared to placebo, the SSRIs and SNRIs did not seem to
reducemigraine frequency at two- or three-month follow-up. Nei-
ther SSRIs nor venlafaxine were better than amitriptyline. Among
other secondary outcomes, again SSRIs or SNRIs did not ame-
liorate migraine intensity, duration, or migraine index, and did
not reduce the consumption of analgesic drugs when compared
to placebo. Amitriptyline appeared to be similar to venlafaxine in
reducing migraine intensity and duration. The data on the safety
profiles of SSRIs and SNRIs derived from the included studies are
also limited. No differences in terms of withdrawals due to adverse
events or minor adverse events were detected, but the number of
events were few and their reporting generally unclear. SSRIs and
SNRIs appear to be better tolerated than amitriptyline but no firm
conclusions can be drawn on the basis of the included trials.
We included three new trials in this update, which did not provide
any substantial new evidence in the field. Overall, these results are
based on 10 studies comparing SSRIs or SNRIs with placebo or
other antidepressants (amitriptyline), and one head-to-head com-
parison. We did not find studies comparing SSRIs and SNRIs
with non-antidepressant drug treatments for preventing migraine
(beta-blockers, antiepileptics, etc.) or with physical or behavioural
treatments for migraine.
Many indexes, scales, and sub-scales were used in this relatively
small number of trials. The clinical relevance of some of these
rating tools is questionable (Thornley 1998). The only scales that
have been formally evaluated are those that assess patients for de-
pressed mood (e.g. Zung Depression Scale or Montgomery and
Asberg Depression Scale), a secondary outcome in the manage-
ment of chronic pain conditions (Snow 2002). Furthermore, the
working hypothesis of these trials is that the overall effect of SS-
RIs or SNRIs is not due to a direct antidepressant effect (Sindrup
2000). Thus, SSRIs or SNRIs need to be compared with non-
antidepressant prophylactic drugs or non-pharmacologic preven-
tive treatments in order to avoid the confounding effects of the
antidepressant therapy.
Only two studies considered symptomatic/analgesic medication
use as an outcome of interest (Ozyalcin 2005; Steiner 1998).Med-
ication use may be more difficult to interpret than migraine fre-
quency (as measured by daily self report) because it is based on a
behavioural response on the part of the patient (taking medication
for acute relief ) to the occurrence of a headache, which introduces
an extra layer of variability. Accordingly, while the use of medi-
cations may be a less direct measure of their effect on migraine
compared to attack frequency, we believe it is a desirable secondary
outcome, particularly since the overuse of acute medication may
perpetuate or increase chronic migraines (Kaniecki 2003).
Pain associated with migraine affects many aspects of an individ-
ual’s life, including both social and occupational roles. We did not
find any mention of workdays lost or any data pertaining to cost-
effectiveness or quality of life. Workdays lost is a specific, strong
measure to assess headache improvement from a more social-eco-
nomic perspective. Several quality of life scales have been validated
and are now available. They assess the impact of migraine on daily
activities and include many items related to individuals’ general
well-being such as pain and mood states. Many headache indexes
replicate a sub-scale or items already included in quality of life
scales. Finally, quality of life is a global measure capable of mak-
ing useful comparisons between adverse events of drugs (Hotopf
1997).
Only one study compared a SSRI to a SNRI and it reported no dif-
ference between escitalopram and venlafaxine in terms of migraine
frequency (Tarlaci 2009). We cannot draw any conclusion about
the fact that differences in selectivity (serotonin or nor adrenaline
reuptake) could be related to differences in efficacy.
Overall completeness and applicability of
evidence
The data that inform this review are few and generally poor, in
terms of the quality of the trials that originated them. Only five
studies reported data on the most relevant clinical outcome, mi-
graine frequency (twoplacebo- and three amitriptyline-controlled)
for a total of fewer than 300 participants. Reporting was often in-
complete, making some studies uninformative. The applicability
of this scarce evidence is also an issue, mainly because the analysed
studies used short follow-up and outcomes with a small clinical
value. However, the findings of this review suggest that SSRIs and
SNRIs do not show benefits for the outcomes that may matter to
patients.
Quality of the evidence
The majority of the included trials can be considered to be at un-
clear risk of bias (see Risk of bias in included studies). None of
the trials reported any information on allocation concealment, or
the blinding of the treatment allocation. Blinding of participants
and study personnel was described in only a few studies. Many
trials were likely to be underpowered, had missing intention-to-
treat analysis and had a strong inclination to perform multiple
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testing. The small study size is a consistent marker of overestima-
tion of treatment effects. Finally, there were frequently ambigui-
ties in the presentation of the results of the analyses, emphasising
within-group comparisons. Some readers may find these method-
ological problems surprising; we did not. Previous methodolog-
ical work showed that these are common problems in studies of
SSRIs and related antidepressants (Hotopf 1997; Hotopf 1999;
Thornley 1998) and, more generally, can be found across many
medical specialties (Altman 1990).Methodological quality did not
seem to have improved in the more recent trials.
Even though we did not formally explore outcome reporting bias,
the use of multiple outcomes without a predefined primary out-
come, with no prespecified priorities among outcomes, and with-
out knowing whether outcomes are equally correlated, may have
increased the risk of data dredging and distorted reporting in an at-
tempt to demonstrate post hoc differences between interventions
(Pocock 1997). This problem is magnified by the limited size of
most included trials.
We rated the overall quality of the evidence for clinically relevant
efficacy and safety outcomes as ’low’ or ’very low’ (Summary of
findings for themain comparison and Summary of findings 2).We
downgraded the overall quality of the evidence for each outcome
because of limitations in the study designs and imprecision. We
also downgraded the outcomes ’migraine index’ and ’withdrawals
(for any reasons and due to adverse events)’ for indirectness. Our
choice was driven by the fact that migraine indexes, as well as the
definitions of adverse events, varied among the trials, and their
applicability and appropriateness to the clinical context might be
questionable.
Agreements and disagreements with other
studies or reviews
Other systematic reviews (Tomkins 2001 and its update in Jackson
2010) have examined antidepressant medication formigraine pro-
phylaxis. On the basis of four studies, which were also included
in our review, the authors concluded that tricyclic antidepressants
reduced the pain from migraine, citing some evidence about their
superiority over SSRIs. The studies included in our review sug-
gested a similar trend, however we cannot conclude that one class
of drug is a better option than the other.
Recent clinical guidelines from the USA considered the role of
antidepressants in migraine prophylaxis (Silberstein 2012). It was
suggested that SSRIs and venlafaxine were probably effective, al-
though the authors cautiously assessed the overall evidence sup-
porting this recommendation as either negative or equivocal. This
recommendation, possibly favouring the use of SSRIs and SNRIs
as a preventive strategy, seems to be generous. A more balanced
message is provided by the National Institute for Health and Care
Excellence (NICE) and Canadian guidelines in which SSRIs and
SNRIs are either not considered at all or are not indicated as a
suitable option (NICE 2012; Pringsheim 2012), in preference to
more effective strategies (e.g. topiramate or propranolol). Even in
patients with migraine, concomitant depression, and/or anxiety,
the role of SSRIs and SNRIs should be considered as limited given
the paucity of evidence.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Since the last version of this review, we included three new rele-
vant studies, which have provided little new evidence on the ef-
fectiveness of selective serotonin reuptake inhibitors (SSRIs) and
serotonin-norepinephrine reuptake inhibitors (SNRIs) in patients
with migraine. SSRIs or SNRIs are no more effective than placebo
and are likely to be less effective than amitriptyline in preventing
migraine. Fluoxetine was themost studied SSRI, while venlafaxine
was the only SNRI under investigation.
The usefulness of SSRIs or SNRIs for preventing migraine is ob-
scure and the best guess is that these drugs are unlikely to be ef-
fective for the majority of patients. When compared to placebo or
amitriptyline, SSRIs and SNRIs did not show any superiority on
relevant outcomes (migraine frequency, intensity, duration). There
was some evidence that SSRIs are better tolerated than amitripty-
line and venlafaxine. The issue of long-term treatment (more than
three months) with respect to efficacy and tolerability should still
be addressed because in real-life conditions, patients with chronic
migraine receive treatment for more than a few weeks.
No conclusion can be drawn on the use of antidepressants with
respect to other prophylactic pharmacological treatments, such
as antihypertensives (e.g. angiotensin-converting enzyme (ACE)
inhibitors and angiotensin II receptor antagonists, beta-blockers,
calcium channel antagonists) or antiepileptics.
Implications for research
Overall, the standards in terms of design and reporting of ran-
domised clinical trials still need to be improved. For example, open
designs are not acceptable in this context. Migraine frequency
should be the primary outcomemeasure in any new trial.Migraine
is a recurrent condition that persists over long periods of time/
whole parts of the lifespan, therefore longer follow-up is needed
and harder outcomes that relate to real-life should be assessed (e.g.
migraine frequency, acutemedication use, days off work, and qual-
ity of life) (Tfelt-Hansen 2012). Thiswill also avoid the use of non-
validated indexes, discouraging multiple comparisons at different
time points, with the warning that multiple data testing easily re-
sults in misleading statistically significant findings that appear by
chance (Moja 2005; Thornley 1998). Standardised collection of
outcomes as suggested by the COMET (Core Outcome Measures
in Effectiveness Trials) Initiative, which is engaged in developing,
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applying, and promoting core outcomes sets (COS), using rigor-
ous consensus methods, for effectiveness trials (Williamson 2012)
could be helpful. The sample size should be carefully estimated
on the basis of the available evidence and the expected effect, in
order to protect the study against random error.
During the current update, we noticed a clear reduction in the
number of publications testing SSRIs and SNRIs in the prophy-
laxis of migraine. For several clinically relevant outcomes, we re-
ported a low level of evidence. This indicates that “further re-
search is very likely to have an important impact on our confi-
dence in the estimate of effect and is likely to change the esti-
mate” (Guyatt 2008). Under this assumption, amitriptyline could
still be suggested as a reference comparator to be used in clinical
trials comparing antidepressants for prevention of migraine. The
limited number of studies on SNRIs retrieved by this review may
suggest that further exploration of the role of these drugs, such as
duloxetine, is needed in migraine prevention. However, overall,
we think that the value of new studies comparing different antide-
pressants in this setting is questionable. A randomised controlled
trial comparing a SSRI or a SNRI versus another drug or another
non-pharmacological intervention is not a priority in themigraine
research pipeline and might not exert a significant impact on the
overall evidence. Other preventive strategies are likely to be the
target of future research. In the field of antidepressants, exploring
the efficacy and safety SSRIs or SNRIs in depressed patients with
migraine might be of greater interest, as optimal treatments and
the role of weak antidepressants are still debatable.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adly 1992
Methods Single-centre, double-blind, randomised, parallel study: fluoxetine versus placebo
No control for symptomatic/analgesic medications use
Participants Country: USA
N = 32 participants
Sex: 3 M, 15 F (sex not reported for drop-outs)
Mean age: fluoxetine 34, placebo 41
Diagnosis: migraine according to Ad hoc Committee on Classification of Headache (Ad
Hoc 1962)
Exclusion criteria: less then 1 weekly severe disabling migraine headache, concomitant
medical conditions, overuse of alcohol and drugs
Recruitment: volunteers solicited through a local newspaper and paid to participate
(USD 40)
Interventions N = 16 fluoxetine to a maximum of 40 mg/day
N = 16 placebo
Active treatment: 8 weeks
Outcomes 1.MigraineHeadache Score = intensity (scale 1 to 10) * duration * amount ofmedications
used to abort attacks
2. Zung Depression Rating Scale
Notes 14 drop-outs (44%):
Fluoxetine: 7 (4 did not keep appointments, 2 for lack of efficacy,1 for side effects)
Placebo: 7 (2 lack of efficacy, 4 changed their mind, 1 submitted an incomplete diary)
Per protocol analysis
No sample size calculation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk Prescription for fluoxetine or placebo to be
filled by the hospital pharmacy
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
High risk High drop-out rate (44%)
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Adly 1992 (Continued)
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk Financial support not reported
Bank 1994
Methods Single-centre, double-blind, randomised, parallel study: fluvoxamine versus amitriptyline
No control for symptomatic/analgesic medications use
Participants Country: Hungary
N = 64
Sex: 17 M, 47 F
Mean age: 34.5 (SD 7.4) fluvoxamine, 33.5 (SD 8.3) amitriptyline
Diagnosis: migraine with andwithout aura (according to International Headache Society
Criteria, IHS 1988)
Exclusion criteria: tension-type headache, headache due to any physical cause, severe
systemic illness and pregnancy
Interventions N = 32 fluvoxamine 50 mg/day
N = 32 amitriptyline 25 mg/day
Active treatment: 12 weeks
Outcomes 1. Headache Unit Index = number of attacks/number of days in visit period
2. Corrected Headache Unit Index = (intensity of attacks (’1 = mild pain’ to ’3 = severe
pain, preventing any activity’) * duration (hours))/number of days in visit period
3. Headache Index = (number of attacks * intensity)/number of days in visit period
Notes 15 drop-outs (23%):
Fluvoxamine: 5 (2 reasons unknown, 3 for side effects: 1 drowsiness and 2 gastrointestinal
problems)
Amitriptyline: 10 (3 reasons unknown, 7 for side effects: all experienced severe drowsi-
ness)
Per protocol analysis
No sample size calculation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Drugs were given to patients in a closed
envelope
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Bank 1994 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Moderate drop-out rate, unbalanced, rea-
sons not fully reported
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk Financial support not reported
Bulut 2004
Methods Single-centre, randomised, double-blind, cross-over: venlafaxine + amitriptyline versus
amitriptyline + venlafaxine
Participants Country: Turkey
N = 52
Sex: 8 M 44 F
Mean age: 31.9
Diagnosis: migraine with and without aura according to International Headache Society
(IHS 1988)
Exclusion criteria: use of other drugs ordered for prophylactic treatment of migraine in
the 4 weeks before randomisation, depression or other psychiatric disorders, allergy to
venlafaxine and/or amitriptyline, serious diseases such as hepatic or renal dysfunction,
heart disease, and pregnancy or breast feeding
Interventions N = 26 venlafaxine + amitriptyline
N = 26 amitriptyline + venlafaxine
Active treatment: 12 weeks
Outcomes 1. Number of attacks per month
2. Attack intensity
3. Attack duration
Notes 76 patients involved, 52 completers
24 drop-outs: 6 due to side effects, 18 due to other reasons
Washout period: 4 weeks
Per protocol analysis
No sample size calculation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information (randomised)
Allocation concealment (selection bias) Unclear risk No information
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Bulut 2004 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Both drugs were identical in appearance
and were packed in identical bottles
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Overall 24/76 (32%) unbalanced for side
effects; no other info
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk Financial support not reported
Colucci d’Amato 1999a
Methods Single-centre, double-blind, randomised, parallel study: fluoxetine versus placebo
No control for symptomatic/analgesic medications use
Participants Country: Italy
N = 52
Sex: 19 M, 33 F
Mean age: 36.8 (SD 12.4) fluoxetine; 38.8 (SD 15.6) placebo
Diagnosis: migraine without aura, for at least 6 months (according to International
Headache Society Criteria) (IHS 1988)
Exclusion criteria: patient using medications for migraine prophylaxis, severe concomi-
tant neurological and medical disorders, breast feeding and pregnancy
Recruitment: headache service outpatients
Interventions N = 32 fluoxetine 20 mg/day
N = 20 placebo
Active treatment: 24 weeks
Outcomes 1. Pain Total Index = pain intensity (’1 = mild pain’ to ’3 = severe pain, preventing any
activity’) x duration (number of hours of headache per month). The algorithm was as
follows: PTI = (D1 x 1) + (D2 x 2) + (D3 x 3), where 1, 2, and 3 are levels of pain
intensity, and D1, D2, and D3 are the hours of migraine per month with intensity 1, 2,
and 3, respectively
Notes No drop-outs
Per protocol analysis
No sample size calculation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
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Colucci d’Amato 1999a (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Drugs identical in appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk Financial support not reported
Krymchantowski 2002
Methods Single-centre, double-blind, randomised, parallel study: amitriptyline versus amitripty-
line plus fluoxetine
Control for symptomatic/analgesic medications use
Participants Country: Brazil
N = 39
Sex: 13 M, 26 F
Mean age: 36.4 (SD 2.5)
Diagnosis: transformed migraine with overusing symptomatic medications (according
criteria proposed by Silberstein 1996)
Exclusion criteria: patients using medications for migraine prophylaxis or chronic treat-
ment for other clinical and psychiatric conditions, women of childbearing potential not
using contraceptives
Recruitment: no information provided
Interventions N = 19 amitriptyline to a maximum of 40 mg/day
N = 20 amitriptyline to a maximum of 40 mg/day plus fluoxetine to a maximum of 40
mg/day
Active treatment: 9 weeks
Outcomes 1. Headache Index = frequency (number of headache days/30 day) x intensity (’0 = no
headache’ to ’4 = bed rest’)
Notes 12 drop-outs (31%):
Amitriptyline: 6 (4 for incomplete diary, 2 for worsening condition)
Amitriptyline plus fluoxetine: 6 (3 for incomplete diary, 1 for worsening condition, 2
for side effects)
Per protocol analysis
No sample size calculation
Risk of bias
Bias Authors’ judgement Support for judgement
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Krymchantowski 2002 (Continued)
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
All outcomes
Low risk Drugs identical in appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk Moderate drop-out rate, balanced, reasons
fully reported
Selective reporting (reporting bias) Unclear risk No information
Other bias Low risk No financial support provided by drug
companies
Landy 1999
Methods Single-centre, double-blind, randomised, parallel study: sertraline versus placebo
No control for symptomatic/analgesic medications use
Participants Country: USA
N = 27
Sex: 2 M, 25 F
Mean age: 36 (SD 8.6)
Diagnosis: migraine with or without aura for 1 year or longer (according to International
Headache Society Criteria, IHS 1988)
Exclusion criteria: severe systemic illness, pregnancy, lactation, treated for a concomitant
seizures or psychiatric disorder
Recruitment: patients of the Wesley Headache Clinic
Interventions N = 13 sertraline to a maximum of 100 mg/day
N = 14 placebo
Active treatment: 8 weeks
Outcomes 1. Headache Index = intensity (’1 = mild pain’ to ’3 = severe’) x number of occurrences
2. Impairment Index = impairment (’1 = no impairment’ to ’3 = bed rest’) * number of
occurrences
Notes 11 drop-outs (41%):
Sertraline: 7 (6did not complete the study, 1 for side effects: loss of appetite and insomnia)
Placebo: 4 (2 did not return, 2 for side effects: anxiety, nausea, dizziness and sweating)
Per protocol analysis
No sample size calculation
Risk of bias
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Landy 1999 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patient, treating physician, and nurse were
unaware of the group assignment
Incomplete outcome data (attrition bias)
All outcomes
High risk Substantial drop-out rate, unbalanced, rea-
sons not fully reported
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk Financial support not reported
Oguzhanoglu 1999
Methods Single-centre, open-label, randomised, parallel study: fluoxetine versus amitriptyline
No control for symptomatic/analgesic medications use
Participants Country: Turkey
Overall: N = 52; Sex: 6 M, 41 F (sex not reported for drop-outs)
Migraine group: N = 17; Sex: 3 M, 12 F (sex not reported for drop-outs); mean age: 31
Diagnosis: migraine (N = 17), CTTH (N = 14) and ETTH (N = 21), all defined
according to International Headache Society criteria (IHS 1988)
Exclusion criteria: antidepressants use in the previous year, score > 17 Hamilton Depres-
sion Scale
Recruitment: from November 1996 to September 1997, no other information
Interventions N = 22 amitriptyline to a maximum of 50 mg/day
N = 25 fluoxetine 20 mg/day
Duration of active treatment: unclear
Outcomes 1. Headache frequency (number of days with headache/30 days)
2. Pain intensity (not defined)
3. Headache duration (not defined)
Notes Overall, 5 drop-outs (10%) for side effects (2 in the migraine group)
Per protocol analysis
No sample size calculation
Risk of bias
Bias Authors’ judgement Support for judgement
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Oguzhanoglu 1999 (Continued)
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Moderate drop-out rate (2/17, 11.7%),
reasons reported
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk Financial support not reported
Ozyalcin 2005
Methods Single-centre, double-blind, randomised, parallel study: venlafaxine 75 mg versus ven-
lafaxine 150 mg versus placebo
Participants Country: Turkey
N = 60
Sex: 6 M, 54 F
Mean age: 34.25 (SD 8.28) venlafaxine 75 mg; 37.19 (SD 12.37) venlafaxine 150 mg;
38.16 (SD 11.24) placebo
Diagnosis: migraine without aura according to International Headache Society (IHS
1988)
Exclusion criteria: age < 18 or > 70, headache for < 2 years, < 3 attacks or > 10 attacks
per month and > 15 headache days per month. Patients taking other prophylactic treat-
ment not stopped 2 weeks prior the start of the study. Women who were breast feed-
ing, patients with major cardiovascular, metabolic, gastrointestinal, neurologic diseases,
any primary headache disorder other than migraine without aura, and any secondary
headache disorder including drug over use headache disorder
Interventions N = 20 venlafaxine 75 mg
N = 21 venlafaxine 150 mg
N = 19 placebo
Outcomes 1. Number of days with headache
2. Pain intensity
3. Headache duration
4. Analgesic consumption
5. Daily activities
6. Patient satisfaction
7. Adverse events
8. Global tolerance
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Ozyalcin 2005 (Continued)
Notes Lost at follow-up 22% (47 completers)
Per protocol analysis
No sample size calculation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information (randomised)
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No information (double-blinded)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Moderate drop-out rate (13/60 = 21.67%),
balanced (placebo 3/19 = 15.8%, venlafax-
ine 75 mg 5/20 = 25%, venlafaxine 150 mg
5/21 = 23.8%)
Selective reporting (reporting bias) Unclear risk No information
Other bias High risk Grant from Wyeth Ilaclari AS, Istanbul,
Turkey. Blinded study drugs were prepared
by Wyeth Pharmaceuticals, PA, USA
Polisca 1992
Methods Single-centre, double-blind, randomised, parallel study: fluoxetine versus placebo
No control for symptomatic/analgesic medications use
Participants Country: Italy
N = 60
Sex: 22 M, 38 F
Mean age: 43.5 (SD 2.1) fluoxetine; 39 (SD 0.8) placebo
Diagnosis: transformed migraine (chronic daily migraine headache, according to Man-
zoni and Nappi (Nappi 1985), with a 6-year or longer history)
Exclusion criteria: unclear
Recruitment: no information provided
Interventions N = 30 fluoxetine 20 mg/day
N = 30 placebo
Active treatment: 12 weeks
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Polisca 1992 (Continued)
Outcomes 1. Pain Total Index (not defined)
2. Migraine Index (not defined)
3. Frequency (number of headache days/30 days)
4. Symptomatic/analgesic drug consumption
Notes No drop-outs
Article in Italian
The report omits important details
No sample size calculation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Neither doctors nor patients were able to
foresee the assignment (not specified how)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk Financial support not reported
Steiner 1998
Methods Multi-centre, double-blind, randomised, parallel study: S-fluoxetine versus placebo.
Control for symptomatic/analgesic medications use
Participants Country: United Kingdom
N = 53
Sex: 13 M, 40 F
Mean age: 37.5 S-fluoxetine, 39 placebo
Diagnosis: migraine (according to International Headache Society Criteria, IHS 1988)
with a 1-year or longer history and 6 to 18 attacks reported in the previous 3 months
Exclusion criteria: patient using medications for migraine prophylaxis or chronic treat-
ment for depression, breast feeding and pregnancy, drug or alcohol abuse, participation
in previous trials
Recruitment: 3 headache centres in the London region. Patients stratified at each centre
according to historical attack frequency
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Steiner 1998 (Continued)
Interventions N = 27 S-fluoxetine 40 mg/day
N = 26 placebo
Active treatment: 12 weeks
Outcomes Primary efficacy measures:
1. Headache frequency (attacks/28 days)
Secondary efficacy measures:
2. Migraine days/28 days
3. Attack intensity (rating scale from ’1 = mild attack’ to ’3 = severe’)
4. Symptomatic/analgesic drug consumption (dose/attack)
5. Patient’s Global Impression of Disease intensity (0 to 100 mm visual analogue scale)
Notes 65 patients recruited, 53 randomised
20 (38%) drop-outs:
3 for non-adherence to treatment
S-fluoxetine: 9 (4 for side effects; 1 for inadequate response; 4 reason not specified)
Placebo: 8 (4 for side effects, 1 for inadequate response, 3 reason not specified)
Per protocol analysis
Sample size calculation done, drop-out rate higher than expected
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
All outcomes
Low risk Drugs identical in appearance
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Substantial drop-out rate, balanced, reason
fully reported
Selective reporting (reporting bias) Unclear risk No information
Other bias High risk Financial support provided by Sepracor
Inc. (Marlborough, MA, USA)
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Tarlaci 2009
Methods Single-centre, randomised, parallel study: venlafaxine versus escitalopram
Participants Country: Turkey
Overall: N = 93
Sex: 17 M, 76 F (sex not reported for drop-outs)
Mean age: 31.4 ± 7.8
Diagnosis: migraine according to the criteria of the International Headache Society
(ICHD-II 2004)
Exclusion criteria: abnormal systemic and neurological examination; < 3migraine attacks
per month; prophylactic medication for the last 2 months
Interventions N = 35 venlafaxine ranging from 75 mg/day to 150 mg/day
N = 58 escitalopram ranging from 10 mg/day to 20 mg/day
Outcomes 1. Number of attacks at 12 weeks
2. VAS
3. Duration at 12 weeks
Notes 12 drop-outs from venlafaxine group due to adverse events
Lost at follow-up 22% (intention-to-treat analysis claimed but no further information)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information (randomised)
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
High risk Lowdrop-out rate (11.4%)but unbalanced
drop-out in 1 group
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk Financial support not reported
CTTH: Chronic tension-type headache
ETTH: Episodic tension-type headache
PTI: Pain Total Index
SD: standard deviation
VAS: visual analogue scale
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Amelin 2000 Not controlled, only intra-group comparison reported
Andersson 1981 SSRI femoxetine no longer produced by drug company
Bittman 1992 Not randomised
Bussone 1991 Data presented aggregate patients with migraine and chronic tension-type headache
Centonze 2000 Both groups took venlafaxine
Colucci d’Amato 1998 Not randomised
Colucci d’Amato 1999b Not randomised
Colucci d’Amato 2000 Not randomised
Diamond 1989 Not randomised
Foster 1994 Not randomised
Iannacchero 1999 Not randomised
Kangasniemi 1983 SSRI femoxetine no longer produced by drug company
Kathpal 1998 Not randomised
Orholm 1986 SSRI femoxetine no longer produced by drug company
Rampello 2004 Patients with comorbidity of depression, migraine, tension-type headache
Sandrini 1991 Not randomised
Saper 1994 Data presented aggregate patients with migraine and with chronic daily headache
Zeeberg 1981 SSRI femoxetine no longer produced by drug company
SSRI: selective serotonin reuptake inhibitor
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Characteristics of studies awaiting assessment [ordered by study ID]
Dzagnidze 2009
Methods Randomised controlled trial, 3 arms
Participants 68 patients with migraine (6 to 7 attacks per month)
Interventions Venlafaxine 150 mg/day (N = 20); venlafaxine 150 mg/day and metoprolol 100 mg/day (N = 26); placebo (N = 22)
Outcomes Headache frequency, intensity, and duration; symptomatic/analgesic medication use for acute headache attacks.
Outcome assessed but data not provided
Notes Poster presentation
He 2004
Methods Single-centre, randomised trial done in China
Participants 60 patients with migraine
Interventions Fluoxetine 20 mg/day (N = 35); placebo (N = 25)
Outcomes Rate of migraine treatment, general cure rate, serum lipid level
Notes Chinese publication, English abstract
Stanic 2009
Methods Single-centre, 3-arm, randomised trial done in Serbia and Montenegro
Participants 300 patients (men 96, women 204); migraine (International Headache Society (IHS)), 3 to 6 attacks per month
Interventions Sertraline 50 mg/day (N = 100); 75 mg cinnarizine 37.5 mg (N = 100); placebo (N = 100)
Outcomes Migraine attacks
Notes Poster presentation
Togha 2014
Methods Single-centre, double-blind, randomised trial done in Iran
Participants Chronic migraine according to IHS. Number of participants not reported
Interventions Venlafaxine 150 mg; topiramate 100 mg
Outcomes Not reported
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Togha 2014 (Continued)
Notes -
IHS: International Headache Society
Characteristics of ongoing studies [ordered by study ID]
NCT01393522
Trial name or title SAV-MD-25 Title: A randomized double blind placebo control trial of milnacipran for migraine pain
Methods Allocation: randomised
Intervention model: parallel assignment
Masking: double-blind (subject, investigator)
Primary purpose: to evaluate the efficacy of milnacipran in headache pain reduction in subjects with chronic
migraine (CM) without fibromyalgia
Participants Inclusion criteria:
• Individuals between the age of 18 and 65, both genders
• Headache fulfils ICHD-2 criteria for: chronic migraine, or probable medication overuse headache
where individual headaches meet criteria for migraine
• At least 15 headache days/month and at least 8 migraine or probable migraine days/month for the past
3 months, by patient report (including days of headache relieved with a triptan or related compound)
• Age at onset of chronic migraine < 60 years old
Main exclusion criteria:
• Subject has failed >/= 4 adequate preventive trials of antidepressant medications due to lack of efficacy;
at least 1 trial included another SNRI. (An adequate preventive trial defined as at least 6 weeks on
therapeutic dose (150 mg of amitriptyline or nortriptyline or other tricyclic, 150 mg of venlafaxine, 60 mg
of duloxetine))
• Subjects on antidepressant medications, including SNRIs who cannot safely withdraw from those
medications, in the assessment of the PI. Subjects on other headache preventives (beta-blockers,
antiepileptic drugs), at a stable dose for at least 3 months, will be allowed to participate
• Presence of fibromyalgia or another pain or medical disorder that would make it difficult for the
patient to distinguish headache-related quality of life from overall health-related quality of life
Interventions Intervention: milnacipran titration schedule starting with 12.5 mg per day increasing to 50 mg twice a day,
starting with day 1 to day 90 and then tapered down
Control: placebo titrated 1 tablet once a day increased per protocol to 2 tablets twice a day, with a starting
dose of 12.5 mg per day to 50 mg twice a day
Outcomes Evaluating Headache Pain Reduction (time frame: change from baseline after the 90-day reporting period)
Evaluating the improvement of Quality of Life (time frame: change from visit 1 until study completion month
4)
Starting date June 2011
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NCT01393522 (Continued)
Contact information Timothy R Smith, MD; mercyhealthresearch@mercy.net
Notes Study sponsor: Mercy Health Research
Recruitment status: recruiting (verification date: September 2011)
ICHD-2: International Classification of Headache Disorders: 2nd edition
PI: principal investigator
SNRI: serotonin-norepinephrine reuptake inhibitor
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D A T A A N D A N A L Y S E S
Comparison 1. SSRI or SNRI versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Migraine index 3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Follow-up: 8 weeks 3 86 Std. Mean Difference (IV, Random, 95% CI) -0.14 [-0.57, 0.30]
1.2 Follow-up: 12 weeks 1 52 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-0.88, 0.25]
2 Withdrawals - any reason 5 221 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.37 [0.73, 2.56]
3 Withdrawals due to adverse
events
5 221 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.95 [0.70, 5.44]
4 Number of patients with minor
adverse events
2 84 Odds Ratio (M-H, Random, 95% CI) 1.46 [0.47, 4.52]
Comparison 2. SSRI or SNRI versus another active drug (amitriptyline)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Migraine frequency (number of
migraine attacks)
2 96 Std. Mean Difference (IV, Random, 95% CI) 0.04 [-0.72, 0.80]
1.1 SSRI 1 44 Std. Mean Difference (IV, Random, 95% CI) -0.36 [-0.96, 0.24]
1.2 SNRI 1 52 Std. Mean Difference (IV, Random, 95% CI) 0.42 [-0.13, 0.97]
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Analysis 1.1. Comparison 1 SSRI or SNRI versus placebo, Outcome 1 Migraine index.
Review: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults
Comparison: 1 SSRI or SNRI versus placebo
Outcome: 1 Migraine index
Study or subgroup SSRI or SNRI Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Follow-up: 8 weeks
Adly 1992 9 6.22 (5.29) 9 24 (32.68) 20.5 % -0.72 [ -1.69, 0.24 ]
Colucci d’Amato 1999a 32 76.9 (59.6) 20 77.2 (61.9) 60.9 % 0.00 [ -0.56, 0.55 ]
Landy 1999 6 16.7 (6.38) 10 15.6 (17.56) 18.5 % 0.07 [ -0.94, 1.08 ]
Subtotal (95% CI) 47 39 100.0 % -0.14 [ -0.57, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.81, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
2 Follow-up: 12 weeks
Colucci d’Amato 1999a 32 60.6 (66.3) 20 80.3 (52.7) 100.0 % -0.32 [ -0.88, 0.25 ]
Subtotal (95% CI) 32 20 100.0 % -0.32 [ -0.88, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
-2 -1 0 1 2
Favours SSRI or SNRI Favours placebo
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Analysis 1.2. Comparison 1 SSRI or SNRI versus placebo, Outcome 2 Withdrawals - any reason.
Review: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults
Comparison: 1 SSRI or SNRI versus placebo
Outcome: 2 Withdrawals - any reason
Study or subgroup SSRI or SNRI Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Adly 1992 7/16 7/16 20.9 % 1.00 [ 0.25, 3.95 ]
Steiner 1998 11/25 9/25 31.5 % 1.39 [ 0.45, 4.25 ]
Landy 1999 7/13 4/14 17.4 % 2.74 [ 0.61, 12.38 ]
Colucci d’Amato 1999a 0/32 0/20 Not estimable
Ozyalcin 2005 14/41 6/19 30.2 % 1.12 [ 0.36, 3.52 ]
Total (95% CI) 127 94 100.0 % 1.37 [ 0.73, 2.56 ]
Total events: 39 (SSRI or SNRI), 26 (Placebo)
Heterogeneity: Chi2 = 1.13, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours SSRI or SNRI Favours placebo
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Analysis 1.3. Comparison 1 SSRI or SNRI versus placebo, Outcome 3 Withdrawals due to adverse events.
Review: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults
Comparison: 1 SSRI or SNRI versus placebo
Outcome: 3 Withdrawals due to adverse events
Study or subgroup SSRI or SNRI Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Adly 1992 1/16 0/16 6.8 % 7.39 [ 0.15, 372.38 ]
Steiner 1998 4/25 3/25 41.9 % 1.38 [ 0.28, 6.73 ]
Colucci d’Amato 1999a 0/32 0/20 Not estimable
Landy 1999 1/13 2/14 18.9 % 0.53 [ 0.05, 5.55 ]
Ozyalcin 2005 6/41 0/19 32.4 % 4.95 [ 0.82, 29.87 ]
Total (95% CI) 127 94 100.0 % 1.95 [ 0.70, 5.44 ]
Total events: 12 (SSRI or SNRI), 5 (Placebo)
Heterogeneity: Chi2 = 2.84, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours SSRI or SNRI Favours placebo
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Analysis 1.4. Comparison 1 SSRI or SNRI versus placebo, Outcome 4 Number of patients with minor
adverse events.
Review: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults
Comparison: 1 SSRI or SNRI versus placebo
Outcome: 4 Number of patients with minor adverse events
Study or subgroup SSRI Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Adly 1992 3/16 3/16 40.5 % 1.00 [ 0.17, 5.90 ]
Colucci d’Amato 1999a 8/32 3/20 59.5 % 1.89 [ 0.44, 8.18 ]
Total (95% CI) 48 36 100.0 % 1.46 [ 0.47, 4.52 ]
Total events: 11 (SSRI), 6 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours SSRI or SNRI Favours placebo
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Analysis 2.1. Comparison 2 SSRI or SNRI versus another active drug (amitriptyline), Outcome 1 Migraine
frequency (number of migraine attacks).
Review: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults
Comparison: 2 SSRI or SNRI versus another active drug (amitriptyline)
Outcome: 1 Migraine frequency (number of migraine attacks)
Study or subgroup SSRI or SNRI amitriptyline
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SSRI
Bank 1994 24 0.07 (0.05) 20 0.09 (0.06) 48.8 % -0.36 [ -0.96, 0.24 ]
Subtotal (95% CI) 24 20 48.8 % -0.36 [ -0.96, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
2 SNRI
Bulut 2004 26 1.77 (1.39) 26 1.23 (1.14) 51.2 % 0.42 [ -0.13, 0.97 ]
Subtotal (95% CI) 26 26 51.2 % 0.42 [ -0.13, 0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Total (95% CI) 50 46 100.0 % 0.04 [ -0.72, 0.80 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 3.51, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 3.51, df = 1 (P = 0.06), I2 =72%
-2 -1 0 1 2
Favours SSRI or SNRI Favours amtriptyline
A P P E N D I C E S
Appendix 1. Search strategies for identification of studies
MEDLINE (Ovid)
1 Headache/
2 exp Headache Disorders/
3 (headach* or migrain* or cephalgi* or cephalalgi*).mp.
4 1 or 2 or 3
5 exp Serotonin Uptake Inhibitors/
6 (SSRI* or SNRI*).mp.
7 (serotonin* and (reuptake or re-uptake) and inhibitor*).mp.
8 (citalopram or dapoxetin* or escitalopram or fluoxetin* or fluvoxamin* or paroxetin* or sertralin* or desvenlafaxin* or duloxetin*
or milnacipran or venlafaxin*).mp.
9 5 or 6 or 7 or 8
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10 4 and 9
11 randomized controlled trial.pt.
12 controlled clinical trial.pt.
13 randomized.ab.
14 placebo.ab.
15 clinical trials as topic.sh.
16 randomly.ab.
17 trial.ti.
18 11 or 12 or 13 or 14 or 15 or 16 or 17
19 10 and 18
20 exp animals/ not humans.sh.
21 19 not 20
key:
mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supple-
mentary concept, unique identifier
pt=publication type
ab=abstract
fs=floating subheading
EMBASE (Ovid)
1 exp “headache and facial pain”/
2 (headach* or migrain* or cephalgi* or cephalalgi*).mp.
3 1 or 2
4 exp serotonin uptake inhibitor/
5 exp serotonin noradrenalin reuptake inhibitor/
6 (SSRI* or SNRI*).mp.
7 (serotonin* and (reuptake or re-uptake) and inhibitor*).mp.
8 (citalopram or dapoxetin* or escitalopram or fluoxetin* or fluvoxamin* or paroxetin* or sertralin* or desvenlafaxin* or duloxetin*
or milnacipran or venlafaxin*).mp.
9 4 or 5 or 6 or 7 or 8
10 3 and 9
11 crossover procedure/
12 double-blind procedure/
13 randomized controlled trial/
14 single-blind procedure/
15 random*.mp.
16 factorial*.mp.
17 (crossover* or cross over* or cross-over*).mp.
18 placebo*.mp.
19 (double* adj blind*).mp.
20 (singl* adj blind*).mp.
21 assign*.mp.
22 allocat*.mp.
23 volunteer*.mp.
24 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25 10 and 24
26 (exp Animal/ or Nonhuman/ or exp animal Experiment/) not Human/
27 25 not 26
key: [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drugmanufacturer, device
trade name, keyword]
CENTRAL (The Cochrane Library)
#1 MeSH descriptor Headache, this term only
#2 MeSH descriptor Headache Disorders explode all trees
#3 (headach* or migrain* or cephalgi* or cephalalgi*)
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#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Serotonin Uptake Inhibitors explode all trees
#6 (SSRI* or SNRI*)
#7 (serotonin* and (reuptake or re-uptake) and inhibitor*)
#8 (citalopram or dapoxetin* or escitalopram or fluoxetin* or fluvoxamin* or paroxetin* or sertralin* or desvenlafaxin* or duloxetin*
or milnacipran or venlafaxin*)
#9 (#5 OR #6 OR #7 OR #8)
#10 (#4 AND #9)
PsycINFO (Ovid)
1 exp headache/
2 (headach* or migrain* or cephalgi* or cephalalgi*).mp.
3 1 or 2
4 exp serotonin reuptake inhibitors/
5 exp serotonin norepinephrine reuptake inhibitors/
6 (SSRI* or SNRI*).mp.
7 (serotonin* and (reuptake or re-uptake) and inhibitor*).mp.
8 (citalopram or dapoxetin* or escitalopram or fluoxetin* or fluvoxamin* or paroxetin* or sertralin* or desvenlafaxin* or duloxetin*
or milnacipran or venlafaxin*).mp.
9 4 or 5 or 6 or 7 or 8
10 3 and 9
key: [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]
Clinicaltrial.gov
(headache or migraine) and serotonin
“Intervention studies”
meta Register of controlled trials (www.controlled-trials.com/mrct/search.html)
(headache or migraine) and serotonin
“All registries”
WHO International Clinical Trials Registry Platform (http://apps.who.int/trialsearch/)
(headache or migraine) AND serotonin
Status: “all”
WH A T ’ S N E W
Last assessed as up-to-date: 19 November 2014.
Date Event Description
1 April 2015 Review declared as stable This review will be assessed for further updating in 2020.
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H I S T O R Y
Protocol first published: Issue 1, 2001
Review first published: Issue 3, 2005
Date Event Description
24 January 2014 New citation required and conclusions have changed This is an update of the review ’Selective serotonin
re-uptake inhibitors (SSRIs) for preventing migraine
and tension-type headaches’. We have implemented
the following major changes:
• the intervention includes selective serotonin and
serotonin-norepinephrine reuptake inhibitors;
• the population is adults with episodic and
chronic migraine;
• tension-type headache is the topic of another
Cochrane review;
• the search strategy has been revised to account
for these changes and updated in November 2014.
We included three new studies (253 participants) in
this update (Bulut 2004;Ozyalcin 2005; Tarlaci 2009)
. Overall, we included 11 studies and 585 participants.
We recommend that previous readers of the review
should re-read this update
14 November 2013 New search has been performed We have updated this review to include the results of
a new search and to include a new class of antidepres-
sants (serotonin-norepinephrine reuptake inhibitors).
We have added a study flow chart, ’Risk of bias’ tables,
and ’Summary of findings’ tables
10 August 2009 Amended Contact details updated.
28 October 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
Study concept, protocol, and first version publication: LM, CC, RS.
Selection of studies: RB, CC, CR, DT.
Acquisition of data: RB, CC, CR, DT.
’Risk of bias’ assessment: RB, CC, CR, DT.
Analysis of data: RB, LM.
Drafting of the manuscript: RB.
Interpretation and critical revision of the manuscript for important intellectual content: RB, CC, CR, DT, RS, LM.
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• Italian Cochrane Centre, Italy.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This 2015 update excludes tension-type headache. A separate review on tension-type headache is in press. Summary of findings table
and Risk of bias tables have been added.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Migraine Disorders [∗drug therapy]; Randomized Controlled Trials as Topic; Serotonin Uptake Inhibitors [∗therapeutic use]; Tension-
Type Headache [∗drug therapy]
MeSH check words
Humans
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